Full Text View
Tabular View
No Study Results Posted
Related Studies
Evaluation of Treatment and Prophylaxis of Invasive Fungal Infections in Immuncompromised Patients in Austria (Study P05532)(WITHDRAWN)
This study has been withdrawn prior to recruitment.
Study NCT00704951   Information provided by Schering-Plough
First Received: June 23, 2008   Last Updated: November 24, 2008   History of Changes

June 23, 2008
November 24, 2008
July 2008
May 2011   (final data collection date for primary outcome measure)
Safety: adverse events [ Time Frame: Depending on treatment modality every 2 to 4 weeks ] [ Designated as safety issue: Yes ]
Same as current
Complete list of historical versions of study NCT00704951 on ClinicalTrials.gov Archive Site
  • Baseline: Patient demographic data; Disease history; Underlying diseases; Diagnosis; Previous therapies; Environmental risk factors; Host factors Performance status [ Time Frame: Depending on treatment modality every 2 to 4 weeks ] [ Designated as safety issue: No ]
  • Treatment and follow up period: Performance status; Medication; Duration of treatment; Frequency of infectious episodes; Management of infections [ Time Frame: Depending on treatment modality every 2 to 4 weeks ] [ Designated as safety issue: No ]
  • Adverse events; Survival status [ Time Frame: Depending on treatment modality every 2 to 4 weeks ] [ Designated as safety issue: Yes ]
Same as current
 
Evaluation of Treatment and Prophylaxis of Invasive Fungal Infections in Immuncompromised Patients in Austria (Study P05532)(WITHDRAWN)
P05532 Evaluation of Treatment and Prophylaxis of Invasive Fungal Infections (IFIs) in Immuncompromised Patients in Austria. Version 1, 08-Nov-2007.

The purpose of this program is to determine the frequency of the use of Posaconazole in immunocompromised patients refractory to first line therapy receiving therapeutic treatment based on different pathogens in comparison to other antifungal therapy.

A further objective is to determine the frequency of the use of Posaconazole in immunocompromised patients receiving prophylactic treatment in comparison to other antifungal prophylaxis.

 
 
Observational
Cohort, Prospective
Mycoses
Drug: Posaconazole or alternative fungal treatment
Immunosuppressed/Immunocompromised patients at high risk for invasive fungal infections
 

*   Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.
 
Withdrawn
250
June 2011
May 2011   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Immunocompromised patients with refractory IFI
  • Patients eligible for prophylactic treatment due to anticipated neutropenia for more than 7 days.

Exclusion Criteria:

  • None
Both
 
No
Contact information is only displayed when the study is recruiting subjects
 
 
NCT00704951
Head, Clinical Trials Registry & Results Disclosure Group, Schering-Plough
P05532
Schering-Plough
 
 
Schering-Plough
November 2008

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP